INTERCEPT + 50%

Intercept has been and potentially remains the leader in NASH. Stock prices plummeted in June 2020 after receiving a full response letter from the FDA to its new application for a drug to treat NASH with liver fibrosis. To date, the only commercial Intercept product, Ocaliva (obeticholic acid or OCA), is an approved drug for the treatment of primary biliary cholangitis (PBC). The likelihood of a new product being approved is extremely low.
Revenue is growing from year to year 2018 - 179.8, 2019 - 252.0, 2020 - 312.7.
On March 12, HC Wainwright upgraded the stock to Neutral from Sell.
In the short term, long. Growth potential 50%. Any news of a refusal in a new product carries the risk of a drop in the stock by tens of percent. However, product news is expected no earlier than the end of April.